Clinical Trial Update: Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study [EARLY_Phase 1]

View source ↗

Summary

Phase 1 pilot study exploring whether adding the BRAF inhibitor vemurafenib can enhance radioiodine uptake in patients with BRAF-mutant, radioiodine-refractory …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thyroid Cancer

Drugs mentioned

• Vemurafenib (vemurafenib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Thyroid Carcinoma | EARLY_Phase 1 | Status: COMPLETED